Sartorius
Market Cap
€19.0b
Last Updated
2020/07/07 20:51 UTC
Data Sources
Company Financials +
Executive Summary
Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Moderate growth potential with acceptable track record.
Similar Companies
Share Price & News
How has Sartorius's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SRT has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
3.7%
SRT
0.9%
DE Medical Equipment
2.1%
DE Market
1 Year Return
53.3%
SRT
20.3%
DE Medical Equipment
2.1%
DE Market
Return vs Industry: SRT exceeded the German Medical Equipment industry which returned 20.4% over the past year.
Return vs Market: SRT exceeded the German Market which returned 3% over the past year.
Shareholder returns
| SRT | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.7% | 0.9% | 2.1% |
| 30 Day | -3.4% | -2.8% | -0.8% |
| 90 Day | 22.2% | 15.1% | 20.1% |
| 1 Year | 53.5%53.3% | 21.8%20.3% | 4.2%2.1% |
| 3 Year | 200.6%197.4% | 121.8%117.1% | 3.7%-4.7% |
| 5 Year | 491.3%478.5% | 248.4%234.4% | 10.7%-4.0% |
Price Volatility Vs. Market
How volatile is Sartorius's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Sartorius' (ETR:SRT) Wonderful 483% Share Price Increase Shows How Capitalism Can Build Wealth1 month ago | Simply Wall St
Sartorius Aktiengesellschaft's (ETR:SRT) Stock's On An Uptrend: Are Strong Financials Guiding The Market?2 months ago | Simply Wall St
Is Sartorius (ETR:SRT) Using Too Much Debt?Valuation
Is Sartorius undervalued compared to its fair value and its price relative to the market?
110.38x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SRT (€253) is trading above our estimate of fair value (€94.37)
Significantly Below Fair Value: SRT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SRT is poor value based on its PE Ratio (110.4x) compared to the Medical Equipment industry average (53x).
PE vs Market: SRT is poor value based on its PE Ratio (110.4x) compared to the German market (21.1x).
Price to Earnings Growth Ratio
PEG Ratio: SRT is poor value based on its PEG Ratio (6.9x)
Price to Book Ratio
PB vs Industry: SRT is overvalued based on its PB Ratio (21.4x) compared to the DE Medical Equipment industry average (4.5x).
Next Steps
Future Growth
How is Sartorius forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
16.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRT's forecast earnings growth (16.1% per year) is above the savings rate (0.2%).
Earnings vs Market: SRT's earnings (16.1% per year) are forecast to grow slower than the German market (22.4% per year).
High Growth Earnings: SRT's earnings are forecast to grow, but not significantly.
Revenue vs Market: SRT's revenue (10.9% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: SRT's revenue (10.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRT's Return on Equity is forecast to be high in 3 years time (24.8%)
Next Steps
Past Performance
How has Sartorius performed over the past 5 years?
18.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRT has high quality earnings.
Growing Profit Margin: SRT's current net profit margins (8.7%) are lower than last year (9.3%).
Past Earnings Growth Analysis
Earnings Trend: SRT's earnings have grown by 18.9% per year over the past 5 years.
Accelerating Growth: SRT's earnings growth over the past year (8.2%) is below its 5-year average (18.9% per year).
Earnings vs Industry: SRT earnings growth over the past year (8.2%) underperformed the Medical Equipment industry 8.2%.
Return on Equity
High ROE: SRT's Return on Equity (20.3%) is considered high.
Next Steps
Financial Health
How is Sartorius's financial position?
Financial Position Analysis
Short Term Liabilities: SRT's short term assets (€927.0M) exceed its short term liabilities (€663.2M).
Long Term Liabilities: SRT's short term assets (€927.0M) do not cover its long term liabilities (€1.1B).
Debt to Equity History and Analysis
Debt Level: SRT's debt to equity ratio (87.7%) is considered high.
Reducing Debt: SRT's debt to equity ratio has increased from 55.8% to 87.7% over the past 5 years.
Debt Coverage: SRT's debt is well covered by operating cash flow (38.3%).
Interest Coverage: SRT's interest payments on its debt are well covered by EBIT (58.2x coverage).
Balance Sheet
Next Steps
Dividend
What is Sartorius's current dividend yield, its reliability and sustainability?
0.14%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SRT's dividend (0.14%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.26%).
High Dividend: SRT's dividend (0.14%) is low compared to the top 25% of dividend payers in the German market (3.8%).
Stability and Growth of Payments
Stable Dividend: SRT is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: SRT is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: SRT is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SRT's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
Joachim Kreuzburg (55yo)
17.17yrs
Tenure
€2,061,000
Compensation
Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH. Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengese ...
CEO Compensation Analysis
Compensation vs Market: Joachim's total compensation ($USD2.33M) is below average for companies of similar size in the German market ($USD5.21M).
Compensation vs Earnings: Joachim's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of Executive Board & CEO | 17.17yrs | €2.06m | no data | |
| CFO, Member of Executive Board and Head of Finance | 2.5yrs | €922.00k | no data | |
| Head of Lab Products & Services Division and Member of Executive Board | 1.5yrs | €991.00k | no data | |
| Head of Bioprocess Solutions Division & Member of Executive Board | 1.5yrs | €861.00k | no data | |
| Head of Corporate Communications & Investor Relations and Member of Supervisory Board | no data | €56.00k | no data | |
| Senior Vice President of Administration Organization & Auditing | no data | no data | no data | |
| Head of Production - China | no data | no data | no data | |
| Head of Quality Assurance - Mechatronics Division Goettingen | no data | no data | no data | |
| Head of Production & Certification Department - Denver USA | no data | no data | no data | |
| Head of Production Department - India | no data | no data | no data |
2.5yrs
Average Tenure
51yo
Average Age
Experienced Management: SRT's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Head of Corporate Communications & Investor Relations and Member of Supervisory Board | no data | €56.00k | no data | |
| Member of Supervisory Board | 8.67yrs | €107.00k | no data | |
| Member of Supervisory Board | no data | €92.00k | no data | |
| Member of the Supervisory Board | no data | €56.00k | no data | |
| Member of the Supervisory Board | 13.58yrs | €56.00k | no data | |
| Chairman of Supervisory Board | 3yrs | €246.00k | 27.37% €5.2b | |
| Member of Supervisory Board | 3.25yrs | €53.00k | no data | |
| Member of the Supervisory Board | 8.25yrs | €45.00k | no data | |
| Member of the Supervisory Board | 8.25yrs | €56.00k | no data | |
| Vice Chairman of the Supervisory Board | 6.33yrs | €137.00k | no data |
8.3yrs
Average Tenure
63yo
Average Age
Experienced Board: SRT's board of directors are considered experienced (8.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sartorius Aktiengesellschaft's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sartorius Aktiengesellschaft
- Ticker: SRT
- Exchange: XTRA
- Founded: 1870
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €18.990b
- Shares outstanding: 68.39m
- Website: https://www.sartorius.com
Number of Employees
Location
- Sartorius Aktiengesellschaft
- Otto-Brenner-Strasse 20
- Göttingen
- Lower Saxony
- 37079
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SART.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jan 1992 |
| SRT | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jan 1992 |
| SRT3 | DB (Deutsche Boerse AG) | Preference Shares | DE | EUR | Jan 1992 | |
| SRT | XTRA (XETRA Trading Platform) | Yes | Ordinary Shares | DE | EUR | Jan 1992 |
| SRT3 | XTRA (XETRA Trading Platform) | Preference Shares | DE | EUR | Jan 1992 | |
| 0NIQ | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| 0NIR | LSE (London Stock Exchange) | Preference Shares | GB | EUR | Jan 1992 | |
| SUVP.F | OTCPK (Pink Sheets LLC) | Preference Shares | US | USD | Jan 1992 | |
| SRT3D | BATS-CHIXE (BATS 'Chi-X Europe') | Preference Shares | GB | EUR | Jan 1992 | |
| SRT3 | SWX (SIX Swiss Exchange) | Preference Shares | CH | CHF | Jan 1992 | |
| SRT3 | WBAG (Wiener Boerse AG) | Preference Shares | AT | EUR | Jan 1992 | |
| SRT | ETLX (Eurotlx) | Yes | Ordinary Shares | IT | EUR | Jan 1992 |
| SRT3 | ETLX (Eurotlx) | Preference Shares | IT | EUR | Jan 1992 |
Biography
Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers live cell analysis system, and cell analysis reagents and consumables; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors. It also provides lab filtration and purification devices; sterile and virus filtration, crossflow filtration, harvesting, prefiltration, membrane chromatography, air/gas filtration, and integrity testing devices; and liquid storage and shipping, freeze and thaw, mixing, proven integrity, transferring and sampling, connecting and disconnecting, and final filling management products. In addition, the company offers process control and data analytics products, such as process analyzers, automation modules, and data analytics and chemometrics; and microbiology products, and lab water purification systems. Further, it provides lab balances, mass comparators and metrology, moisture analyzers, specialty weighing solutions, weighing accessories, weights/weight sets, paint mixing solutions, and OEM weigh cells; and OEM membrane and device, pipetting and dispensing, and connectivity solutions. Additionally, the company offers bioprocess development engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, cannabis testing, food and beverage, environmental, and paint mixing industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/07 20:51 |
| End of Day Share Price | 2020/07/07 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.